

## Regulatory Announcement

**Company** Akers Biosciences  
**TIDM** AKR  
**Headline** Placing Update  
**Released** 15:50 12-Jun-08

RNS Number : 6051W  
Akers Biosciences, Inc.  
12 June 2008

### Akers Biosciences, Inc. ("ABI" or the "Company")

#### Placing update

Further to the announcement on 11 June 2008 that a consortium of private investors, acting through Saltburn Limited, a company incorporated in the Channel Islands, had exercised an option, granted by the Company on 4 June 2008, to invest £2.275m into ABI, by way of a subscription for 17,500,000 new common shares ("Shares"), the Company announces that admission of these Shares to trading on AIM is now expected to take place on 20 June 2008.

Admission of the 22,768,824 new common shares (as a result of the conversion by Brittany Capital) to trading on AIM, is expected to take place on 13 June 2008

Enquiries:

Thomas A. Nicolette  
President and CEO  
Tel. +1 856 848 8698

Ben Simons or Eleanor Williamson  
M: Communications  
Tel. +44 (0)20 7153 1540

Alasdair Younie  
Arbuthnot Securities Limited  
Tel. +44 (0)20 7012 2139

This information is provided by RNS  
The company news service from the London Stock Exchange

END